2025
HGKGY Power Assets Holdings Ltd
ICPT Intercept Pharmaceuticals Inc
KEY KeyCorp
TTWO Take-Two Interactive Software Inc
TOPS Top Ships Inc
BOLT Bolt Biotherapeutics Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Based in United Kingdom

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Closing Price: $11.68

Day's Change: -0.87 (-6.93%)

Bid: --

Ask: --

B/A Size: --

Day's High: 12.00

Day's Low: 11.51

Volume (Heavy Day) Volume: 17,250,635 10-day average volume: 8,405,155: 17,250,635

Unable to locate that news article. Back to news results

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and